# Clinical Cases: Menopause and Perimenopause

## Case 1: Vasomotor Symptoms and Hormone Therapy Initiation

### Patient Demographics
- **Age:** 52 years
- **Sex:** Female
- **Occupation:** Accountant

### Chief Complaint
"I'm having terrible hot flashes that are ruining my sleep and affecting my work."

### History of Present Illness
The patient presents with a 14-month history of progressively worsening hot flashes and night sweats. She describes sudden episodes of intense heat beginning in her chest and rising to her face, accompanied by flushing, profuse sweating, and palpitations, lasting 2 to 4 minutes each. She estimates she has 10 to 12 hot flashes during the day and 4 to 5 night sweats that wake her from sleep. The night sweats require her to change her pajamas and bedsheets multiple times weekly. She reports significant sleep disruption with an average of only 4 to 5 hours of fragmented sleep per night. She is experiencing fatigue, irritability, difficulty concentrating at work, and depressed mood. Her last menstrual period was 13 months ago. Prior to the cessation of menses, she had 6 months of irregular cycles with intervals ranging from 21 to 60 days.

### Past Medical History
- No significant medical history
- No prior surgeries
- No history of thromboembolism
- No breast cancer or breast biopsies
- Menarche at age 13, previously regular cycles
- G2P2, two uncomplicated vaginal deliveries

### Family History
- Mother alive at 78, history of osteoporosis
- No family history of breast cancer, ovarian cancer, or thromboembolism
- Father deceased at 72 from myocardial infarction

### Medications
- Multivitamin daily
- Calcium 500 mg with vitamin D 400 IU daily

### Physical Examination Findings
- **Vital Signs:** BP 128/78 mmHg, HR 76 bpm, BMI 26 kg/m2
- **General:** Well-appearing woman in no acute distress
- **Thyroid:** Normal size, no nodules
- **Breast:** No masses, no nipple discharge, no axillary lymphadenopathy
- **Cardiovascular:** Regular rate and rhythm, no murmurs
- **Abdomen:** Soft, non-tender, no hepatosplenomegaly
- **Pelvic:** External genitalia with mild labial atrophy, vaginal mucosa pale and dry with loss of rugae, cervix atrophic-appearing, uterus small and non-tender, ovaries not palpable

### Diagnostic Workup
- **FSH:** 68 IU/L (elevated, consistent with menopause)
- **Estradiol:** 12 pg/mL (low, postmenopausal range)
- **TSH:** 2.4 mIU/L (normal, ruling out thyroid dysfunction)
- **Lipid Panel:** Total cholesterol 218 mg/dL, LDL 138 mg/dL, HDL 52 mg/dL, Triglycerides 142 mg/dL
- **Fasting Glucose:** 94 mg/dL (normal)
- **Mammogram:** BI-RADS 1, negative, performed 8 months ago
- **Pap Smear:** Normal, HPV negative, performed 2 years ago

### Diagnosis
**Menopause** with moderate-to-severe vasomotor symptoms significantly impacting quality of life
- Meets diagnostic criteria: 12 months of amenorrhea at appropriate age
- Laboratory confirmation with elevated FSH and low estradiol
- Patient is within the "window of opportunity" (within 10 years of menopause onset, under age 60)

### Management Plan

**Discussion of Treatment Options:**

*Hormone Therapy Considerations:*
- Patient is an appropriate candidate for systemic hormone therapy:
  - Intact uterus present (requires combined estrogen-progestogen)
  - Within window of opportunity (age 52, 1 year postmenopause)
  - No absolute contraindications
  - Moderate-to-severe symptoms significantly impacting quality of life

*Benefits discussed:*
- 75% reduction in hot flash frequency and severity
- Improvement in sleep quality
- Prevention of bone loss
- Improvement in vaginal atrophy symptoms
- Potential mood and quality of life benefits

*Risks discussed:*
- Small increased risk of VTE (approximately doubled with oral; less with transdermal)
- Small increased risk of stroke (primarily with oral estrogen)
- Breast cancer risk with combined therapy increases after approximately 5 years of use
- Gallbladder disease risk with oral estrogen

**Selected Treatment Regimen:**

1. **Transdermal estradiol** 0.05 mg/day patch (applied twice weekly)
   - Transdermal selected due to:
     - Lower VTE risk compared to oral
     - No first-pass hepatic effect (better for her borderline lipids)
     - Steady-state hormone delivery

2. **Micronized progesterone** (Prometrium) 100 mg orally at bedtime nightly (continuous combined regimen)
   - Micronized progesterone selected for:
     - More favorable metabolic profile than synthetic progestins
     - Sedative properties beneficial for her insomnia
     - Continuous combined regimen to achieve amenorrhea

**Alternative discussed:** Levonorgestrel IUD for endometrial protection if she prefers avoiding oral progestogen

**Lifestyle Recommendations:**
1. Avoid known triggers: alcohol, caffeine, spicy foods, hot beverages
2. Layer clothing for easy removal during hot flashes
3. Keep bedroom cool (65-68 degrees F)
4. Regular aerobic exercise (150 minutes per week)
5. Stress reduction techniques

**Follow-up Plan:**
1. Return in 3 months to assess symptom response and side effects
2. Mammogram annually
3. If inadequate response at 3 months, consider increasing to 0.075 mg transdermal patch
4. Annual reassessment of need for continued therapy
5. Bone density screening at age 65 (or earlier if risk factors develop)

**Counseling Points:**
- Hormone therapy is the most effective treatment for vasomotor symptoms
- Start at low dose and titrate to symptom control
- No arbitrary time limit on duration; annual reassessment recommended
- Transient breast tenderness and vaginal spotting may occur initially
- Report any unexpected vaginal bleeding after the first 6 months

### Clinical Image
![Menopause Symptoms Diagram](case_01_image.jpg)

**Image Description:** Diagram illustrating the spectrum of menopausal symptoms including vasomotor symptoms (hot flashes, night sweats), genitourinary symptoms (vaginal dryness, urinary frequency), psychological symptoms (mood changes, sleep disturbance, cognitive changes), and musculoskeletal symptoms (joint pain). The diagram demonstrates the multi-system effects of estrogen deficiency.

**Attribution:** Image adapted from Wikimedia Commons, "Symptoms of menopause (vector).svg" by Mikael Haggstrom. Licensed under CC BY-SA 4.0. Source: https://commons.wikimedia.org/wiki/File:Symptoms_of_menopause_(vector).svg

---

## Case 2: Genitourinary Syndrome of Menopause

### Patient Demographics
- **Age:** 62 years
- **Sex:** Female
- **Occupation:** Retired nurse

### Chief Complaint
"Sex has become too painful and I keep getting bladder infections."

### History of Present Illness
The patient presents with a 3-year history of progressively worsening vaginal dryness and painful intercourse. She describes the pain as a burning and tearing sensation at the vaginal opening that persists for hours after intercourse. Over the past 18 months, she has had four documented urinary tract infections requiring antibiotic treatment. She reports urinary urgency, frequency (voiding 10 to 12 times daily), and occasional urgency incontinence with small-volume leakage. She also notes vaginal itching and occasional spotty discharge. She has tried over-the-counter lubricants with only minimal improvement. Her menopausal symptoms (hot flashes) resolved approximately 5 years ago. She has been postmenopausal for 12 years and never used hormone therapy. She is sexually active with her husband of 38 years and reports that the vaginal symptoms have significantly impacted their intimate relationship.

### Past Medical History
- Breast cancer, hormone receptor-positive, stage IA, diagnosed 6 years ago
- Treated with lumpectomy and radiation followed by 5 years of anastrozole (aromatase inhibitor)
- Completed anastrozole therapy 1 year ago
- Hypertension, well-controlled
- No history of VTE

### Medications
- Lisinopril 10 mg daily
- Calcium 600 mg with vitamin D 800 IU twice daily

### Physical Examination Findings
- **Vital Signs:** BP 124/76 mmHg, HR 72 bpm, BMI 27 kg/m2
- **Breast:** Well-healed lumpectomy scar right breast, no masses, no axillary nodes
- **External Genitalia:** Significant labial atrophy with loss of subcutaneous fat, urethral meatus prominent and slightly erythematous
- **Vaginal Examination:** Vaginal introitus narrowed, speculum insertion uncomfortable, vaginal mucosa pale, thin, dry with loss of rugae, petechiae visible on posterior vaginal wall, minimal clear discharge, pH 6.0 (elevated)
- **Bimanual Examination:** Small atrophic uterus, ovaries not palpable, no adnexal tenderness

### Diagnostic Workup
- **Vaginal pH:** 6.0 (elevated; normal premenopausal 3.5-4.5)
- **Wet Mount:** Parabasal cells predominant (consistent with atrophy), no trichomonads, no clue cells, no yeast
- **Urinalysis:** Negative for infection currently
- **Post-Void Residual:** 25 mL (normal)
- **Mammogram:** BI-RADS 2, benign findings, 4 months ago

### Diagnosis
**Genitourinary Syndrome of Menopause (GSM)** with:
1. Vulvovaginal atrophy causing dyspareunia
2. Urogenital atrophy contributing to recurrent UTIs
3. Overactive bladder symptoms (urgency, frequency, urgency incontinence)

*Special Consideration:* History of hormone receptor-positive breast cancer requires careful discussion of low-dose vaginal estrogen risks and benefits

### Management Plan

**Discussion of Treatment Options:**

*Consideration in Breast Cancer Survivor:*
- Systemic hormone therapy is contraindicated due to history of hormone receptor-positive breast cancer
- Low-dose vaginal estrogen remains controversial but data suggest:
  - Minimal systemic absorption with low-dose vaginal preparations
  - Serum estradiol levels remain in postmenopausal range
  - No clear evidence of increased breast cancer recurrence risk with low-dose vaginal estrogen
  - Decision should be individualized with oncology input

**Stepwise Management Approach:**

*Step 1 - Non-hormonal therapies (first-line):*
1. **Vaginal moisturizer** (hyaluronic acid-based): Apply 3 times weekly to improve baseline tissue hydration
2. **Lubricant** (silicone or water-based): Use liberally with intercourse
3. **Vaginal dilator therapy**: Graduated dilators to maintain vaginal caliber and prevent further narrowing

*Step 2 - If non-hormonal measures insufficient (after 8-12 weeks):*

**Option A - Low-dose vaginal estrogen (with oncology consultation):**
- Oncology consultation obtained; oncologist supportive of low-dose vaginal estrogen given completion of adjuvant therapy and significant quality of life impairment
- **Estradiol vaginal tablet** (Vagifem) 10 mcg: Insert one tablet vaginally daily for 2 weeks, then twice weekly maintenance
- Lowest effective dose with minimal systemic absorption

**Option B - Non-estrogen hormonal option:**
- **Intravaginal prasterone (DHEA)** 6.5 mg nightly: Metabolized locally to estrogen and androgen; may be more acceptable to some breast cancer survivors
- **Ospemifene** 60 mg orally daily: SERM with estrogen agonist effect on vaginal tissue; FDA-approved for moderate-to-severe dyspareunia; however, label warns about use in breast cancer survivors due to theoretical concerns

**For Recurrent UTIs:**
1. Low-dose vaginal estrogen has been shown to reduce recurrent UTI risk by 50%
2. If vaginal estrogen declined: vaginal probiotic (Lactobacillus) may help restore normal flora
3. Consider prophylactic antibiotics if UTIs continue despite vaginal therapy

**For Urinary Urgency/Frequency:**
1. Behavioral modifications: timed voiding, bladder training
2. Pelvic floor physical therapy referral
3. If vaginal estrogen improves tissue health, OAB symptoms often improve
4. If persistent OAB: consider antimuscarinic medication

**Follow-up Plan:**
1. Return in 8 weeks to assess response to initial non-hormonal therapy
2. If insufficient improvement, initiate low-dose vaginal estrogen after informed consent and oncology clearance
3. Annual mammography per oncology surveillance
4. No routine monitoring of serum estradiol needed with low-dose vaginal preparations

**Patient Counseling:**
- GSM is chronic and progressive without treatment
- Non-hormonal options may provide partial relief
- Low-dose vaginal estrogen is the most effective treatment
- Systemic absorption with vaginal estrogen is minimal with approved low-dose preparations
- Treatment will need to continue long-term as symptoms return upon discontinuation

### Clinical Image
![Vaginal Atrophy Comparison](image_01.png)

**Image Description:** Comparison diagram showing premenopausal estrogenized vaginal epithelium (thick, pink, rugated with normal pH 3.5-4.5) versus postmenopausal atrophic epithelium (thin, pale, smooth, with elevated pH above 5.0). The atrophic epithelium shows loss of superficial cells and predominance of parabasal cells on cytology.

**Attribution:** Educational diagram demonstrating vaginal epithelial changes in menopause. Similar to images available on Wikimedia Commons in Category:Menopause (https://commons.wikimedia.org/wiki/Category:Menopause).

---

## Case 3: Premature Ovarian Insufficiency

### Patient Demographics
- **Age:** 34 years
- **Sex:** Female
- **Occupation:** Software engineer

### Chief Complaint
"My periods stopped 6 months ago and my doctor says I might be in menopause."

### History of Present Illness
The patient presents for evaluation of secondary amenorrhea of 6 months duration. She had regular monthly menstrual cycles until approximately 8 months ago when her cycles became irregular, with intervals of 6 to 8 weeks. Her last menstrual period was 6 months ago. Over the past 4 months, she has developed hot flashes occurring 4 to 5 times daily, night sweats, vaginal dryness, and difficulty sleeping. She reports fatigue, depressed mood, and difficulty concentrating at work. She denies significant weight change, excessive exercise, or major stressors. She and her husband have been trying to conceive for the past year without success. She had one uncomplicated pregnancy 3 years ago resulting in a healthy child via vaginal delivery.

### Past Medical History
- G1P1, one prior pregnancy
- No autoimmune disorders
- No chemotherapy or pelvic radiation
- No prior ovarian surgery
- Regular Pap smears, all normal

### Family History
- Mother underwent menopause at age 51
- Maternal aunt with early menopause in her late 30s
- No known family history of fragile X syndrome or intellectual disability
- Sister with Hashimoto thyroiditis

### Physical Examination Findings
- **Vital Signs:** BP 110/70 mmHg, HR 68 bpm, BMI 22 kg/m2
- **General:** Well-appearing woman, appears stated age
- **Thyroid:** Mildly enlarged, no nodules
- **Breast:** No masses or discharge
- **Pelvic:** Normal external genitalia, vaginal mucosa slightly pale and dry, cervix normal, uterus normal size and mobile, ovaries not palpable

### Diagnostic Workup
- **FSH (x2 measurements 4 weeks apart):** 62 IU/L and 58 IU/L (both elevated, confirming hypergonadotropic state)
- **Estradiol:** 18 pg/mL (low)
- **AMH:** 0.1 ng/mL (severely diminished ovarian reserve)
- **LH:** 45 IU/L (elevated)
- **Prolactin:** 12 ng/mL (normal)
- **TSH:** 8.2 mIU/L (elevated)
- **Free T4:** 0.7 ng/dL (low-normal)
- **Anti-TPO Antibodies:** Positive at 340 IU/mL (confirming autoimmune thyroiditis)
- **Urine Pregnancy Test:** Negative
- **Karyotype:** 46,XX (normal female)
- **FMR1 Premutation Testing:** Negative for fragile X premutation
- **Anti-adrenal Antibodies (21-hydroxylase):** Negative
- **Morning Cortisol:** 14 mcg/dL (normal)
- **Pelvic Ultrasound:** Uterus normal size and morphology, endometrial thickness 4 mm, bilateral ovaries small (right 1.8 cm3, left 2.0 cm3) with minimal antral follicles (total AFC 3)

### Diagnosis
**Premature Ovarian Insufficiency (POI)** (previously called premature ovarian failure or premature menopause)
- Defined as: Ovarian insufficiency before age 40 with elevated FSH (>30-40 IU/L on two occasions 4 weeks apart) and estrogen deficiency
- Associated **Hashimoto Thyroiditis** (autoimmune thyroid disease)
- Etiology: Likely autoimmune given positive anti-TPO antibodies and associated thyroiditis; negative for fragile X premutation

### Management Plan

**Immediate Management:**

1. **Emotional Support and Counseling:**
   - Acknowledge the profound emotional impact of this diagnosis
   - Referral to counselor or therapist experienced with reproductive issues
   - Patient education about POI vs. menopause (POI can have intermittent ovarian function)
   - Support group resources (e.g., International Premature Ovarian Failure Association)

2. **Hormone Therapy - Essential for Health:**
   - Unlike menopause at typical age, women with POI should receive hormone replacement until at least age 50-51 (average age of natural menopause)
   - Benefits in POI:
     - Bone health protection (prevent premature osteoporosis)
     - Cardiovascular protection
     - Vasomotor symptom relief
     - Genitourinary health
     - Quality of life and mood
     - Potential cognitive benefits

   **Recommended Regimen:**
   - **Transdermal estradiol** 100 mcg/day (higher dose than typical menopause HT to approximate premenopausal levels)
   - **Cyclic micronized progesterone** 200 mg orally for 12-14 days per month (to allow for potential spontaneous ovulation and pregnancy detection)
   - Alternative: Combined oral contraceptive if not attempting pregnancy (provides reliable estrogen/progestogen and contraception)

3. **Thyroid Disorder Management:**
   - Start **levothyroxine** 50 mcg daily for newly diagnosed hypothyroidism
   - Repeat TSH in 6 weeks, titrate to TSH goal 0.5-2.5 mIU/L
   - Annual thyroid monitoring lifelong

**Fertility Counseling:**

1. **Spontaneous pregnancy possibility:**
   - 5-10% of women with POI may conceive spontaneously due to intermittent ovarian function
   - Use cyclic progestogen rather than continuous to allow detection of pregnancy
   - Counsel that this is unpredictable and should not be relied upon

2. **Options for family building:**
   - **Donor egg IVF:** Most successful option, 50-60% success rate per cycle
   - **Embryo donation**
   - **Adoption**
   - Referral to reproductive endocrinologist for detailed counseling

**Bone Health:**
1. Baseline DXA scan given early estrogen deficiency
2. Calcium 1200 mg daily and vitamin D 800-1000 IU daily
3. Weight-bearing exercise

**Cardiovascular Risk:**
1. Assess and modify traditional risk factors
2. Hormone therapy provides cardiovascular protection in young women with POI
3. Annual lipid monitoring

**Additional Autoimmune Screening:**
1. Given positive anti-TPO antibodies, screen for other autoimmune conditions:
   - Fasting glucose (type 1 diabetes)
   - Celiac antibodies
   - Consider adrenal antibodies periodically even though initially negative

**Follow-up Plan:**
1. Return in 6 weeks for thyroid recheck and HT assessment
2. DXA at baseline, repeat in 2 years
3. Annual comprehensive visit including cardiovascular risk assessment
4. Genetic counseling regarding implications for any daughters (fragile X negative but family history of early menopause suggests possible genetic component)
5. Continue hormone therapy until at least age 50-51

### Clinical Image
![Ovarian Reserve Assessment](image_02.png)

**Image Description:** Diagram illustrating the assessment of ovarian reserve showing AMH levels, antral follicle count on ultrasound, and FSH levels across the spectrum from normal ovarian reserve to diminished ovarian reserve to premature ovarian insufficiency. The ultrasound image component shows comparison between a normal ovary with multiple antral follicles versus an ovary with POI showing minimal follicles and small volume.

**Attribution:** Educational diagram for ovarian reserve assessment. FSH and AMH patterns in premature ovarian insufficiency as described in medical literature.

---

## Summary of Key Learning Points

1. **Hormone therapy for vasomotor symptoms:**
   - Most effective treatment (75% reduction in hot flashes)
   - Best initiated within window of opportunity (<10 years postmenopause, <60 years old)
   - Transdermal preferred for lower VTE risk
   - Combined estrogen-progestogen required with intact uterus

2. **Genitourinary syndrome of menopause:**
   - Chronic and progressive without treatment
   - Low-dose vaginal estrogen is most effective
   - Minimal systemic absorption with approved preparations
   - Can be considered in breast cancer survivors with oncology guidance

3. **Premature ovarian insufficiency:**
   - Defined as ovarian failure before age 40
   - Requires workup for etiology (karyotype, FMR1, autoimmune)
   - Hormone therapy is essential until age 50-51 for health protection
   - 5-10% spontaneous pregnancy rate; donor egg IVF is primary fertility option

4. **Non-hormonal options** include SSRIs/SNRIs, gabapentin, fezolinetant, and cognitive behavioral therapy for vasomotor symptoms

5. **Annual reassessment** of hormone therapy benefits and risks is recommended; no arbitrary time limits on duration